Value-Based Pricing
Value-Based Pricing (VBP) aligns the price of a treatment with the value it provides to patients, healthcare systems, and society. Across multiple indications, a single price may not accurately reflect a medicine’s value, Indication-Based Pricing (IBP) allows different prices to be set for different indications.
Around the World in HTAs: Saudi Arabia – Navigating the healthcare and HTA landscape
24 September 2025
The next stop in our around the world in HTAs adventure is Saudi Arabia. This blog breaks down how the Kingdom is reshaping access to new health technologies through regulatory reform, a formal HTA framework, and value-based care. It provides a comprehensive overview of the structural and regulatory reforms underway as part of Vision 2030, highlighting how these changes are reshaping the way new health technologies are evaluated, priced, and brought to market.
Understanding the Full Value of Long-Acting Therapies: less is more?
7 May 2025
Long-acting (LA) therapies represent a significant innovation in pharmaceutical development by offering a sustained drug effect with reduced administration frequency.
The BRAVER Roadmap to Broader Assessment of the Value of Health Interventions in the Asia-Pacific Region
14 April 2025
Health Technology Assessment (HTA) agencies evaluate and make decisions on the use, funding, or reimbursement of health technologies based on clinical and economic evidence.
What is the impact of Uniform Pricing, Indication-Based Pricing (IBP) and alternative commercial arrangements for new pharmaceuticals in the UK NHS?
19 November 2024
A critique of the recent EEPRU paper
Unlocking the Value of Combination Therapies
9 July 2024
Combination therapies (CTs) merge treatments with different mechanisms of action to achieve greater clinical benefits than the individual components alone. CTs are increasingly being used in oncology.
A Framework for Value-aligned Pricing of Combination Therapies
25 June 2024
Combination therapies can provide effective treatment options and improve patient outcomes. However, there are significant barriers to patient access to combination therapies, including the prevailing pricing models used in Europe.
Breaking the European Deadlock: Part 3 – Revenue Guarantee and Subscription Models for New Antibiotics
16 January 2024
Insight 3 of this series provides an exploration of revenue guarantee/subscription models and how they could be implemented in the EU.
Capturing the Broader Value of Antibiotics
23 November 2023
The value of antibiotics often extends beyond what HTA captures. The STEDI framework aims to capture that broader value and our report outlines a roadmap to realising its full potential.
OHE’s AMR consultation response
21 November 2023
This blog summarises our perspective on the recent proposals set out by NHS England to assess the value of new antibiotics via a new scoring system linked to a volume-delinked revenue guarantee payment. Key arguments outlined here were submitted to NHS England as part of OHE’s response to the consultation on proposals.